NBY (novabay.com) Margin reged

NBY (NovaBay Pharmaceuticals) - tandha merek perusahaan

NovaBay Pharmaceuticals relies on third-party operators for the delivery of its ophthalmological solutions to optimize costs. The current gross margin reflects production efficiency trends, with the current value standing at 51.30. Growth potential is driven by closed B2B distribution channels for the Avenova spray and a staff of leading scientists developing innovative eye health products.

Tingkat bathi miturut bathi reged: NovaBay (NBY) kanggo 04.07.2022 - 18.04.2026

Rincian metrik keuangan lan pasar NovaBay (NBY)

Pambiji fundamental:NovaBay Pharmaceuticals
Sampel barang NovaBay Pharmaceuticals Inc.

The assessment of NovaBay Pharmaceuticals (NBY) operational resilience is based on the gross margin, which determines the portion of revenue minus direct production costs, reflecting the efficiency of cost-of-goods-sold management. By analyzing the current gross margin, an investor sees profit stability supported by the optimization of warehouse hubs and the diversification of component supplies for antiseptic products in the US.